spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Nova Biomedical FLEX2 Cell Culture Analyzer

Nova Biomedical

Adds Sample Retain Capability

Waltham, MA–Nova Biomedical announces the addition of a Sample Retain Collector (SRC) for BioProfile FLEX2 cell culture analyzer. The FLEX2 automated cell culture analyzer measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability. A single FLEX2 analyzer with SRC and the previously introduced Online Sampler (OLS) module provides automated sampling and analysis of these key cell culture tests from as many as 10 bioreactors. This FLEX2 automation package saves hours of time versus manual sampling, analysis, sample storage, and after-hours cell culture monitoring.

The SRC automatically collects cell culture samples from the FLEX2 Online Sampler and stores them in a refrigerated environment to fulfill regulatory requirements for long-term sample retains, as well as enabling further offline testing. The SRC allows user-selectable retained sample volumes from 200uL to 50 mL at a storage temperature of 4˚C. In combination with the FLEX2 and OLS, samples from up to 10 bioreactors can be analyzed, and stored by the SRC in as fast as one hour.

Matt McRae, Nova Biotechnology Product Line Manager says “We have partnered with the industry leader in liquid handling systems, Teledyne Cetac, to market this system, configured specifically to work with the FLEX2. The Sample Retain Collection System completes the full automation package for the FLEX2, offering the truly automated sampling, analysis, sample storage and feedback control of all measured parameters that our customers need. It also enables safe storage of retains and/or later analysis of other key cell culture attributes that today’s laboratories require.”

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood point-of-care and critical care analyzers, as well as the most advanced instruments for cell culture monitoring in the biotechnology market. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova’s biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for a broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, and Switzerland.

www.novabiomedical.com
###
phone 781-894-0800
email info@novabio.com
web https://www.novabio.us/home.php
email 200 Prospect Street Waltham, MA 02454-9141 USA
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Thermo Fisher Scientific launches online 2D-LC systems to characterize complex samples

GERMERING, Germany – (February 17, 2021) - Thermo Scientific Vanquish Online 2D-Liquid Chromatography (LC) Systems offer a robust and flexible platform for pharmaceutical/biopharmaceutical R&D, food safety, environmental testing, omics and polymer analysis scientists to characterize complex samples in-depth with the highest confidence.
More info >>


White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

Industry Events

MedTech Integrates 2021

22 June 2021, VIRTUAL CONFERENCE

Inspired by the success of the inaugural MedTech Integrates in last October, Life Science Integrates is delighted to announce the second Medtech Integrates conference. This one-day gathering of technology, diagnostics, devices and therapeutics organisations, as well as clinicians and regulators, provides a platform to discuss the major challenges impacting the MedTech sector.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement